

Eran Seger

Company: Protai Bio Website: www.protai.bio CEO: Eran

CATEGORY: Biotech/Pharma Session: "AI Pharma" drug discovery, Quantum Computing." Topic: Unlocking the therapeutic potential of protein complexes with the power of structural proteomics and AI Protein complexes are crucial drivers of health and disease, making them compelling targets for therapeutic intervention. The rational design of small molecules, whether as proteinprotein interaction (PPI) inhibitors or proximity-inducing agents, is significantly challenged by the dynamic nature of proteinprotein and protein-drug interactions. Current design tools fail to accurately account for this complex dynamism. Protai's AIMS™ platform overcomes this limitation. By integrating experimental structural proteomics data into AI models, AIMS™ provides critical insight into the dynamic state of proteins and their drug-bound forms - enabling structurally informed drug discovery. This presentation will feature Protai's AI-driven AIMS™ framework. We will demonstrate how AIMS™ models facilitate the design of PROTAC compounds with enhanced efficacy and selectivity, through a casestudy of Protai's novel KAT6A degrader.